Saniona
19.60 SEK
-0.61 %
Less than 1K followers
SANION
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-0.61 %
+20.25 %
+47.81 %
+110.75 %
+143.78 %
+185.30 %
+542.56 %
+3.88 %
+400.47 %
Saniona is a biotechnology company focused on developing innovative treatments for neurological and psychiatric diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Saniona was founded in 2011 and is headquartered in Denmark.
Read moreMarket cap
2.71B SEK
Turnover
28.89M SEK
Revenue
334.67M
EBIT %
72.28 %
P/E
11.07
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.2
2026
Annual report '25
27.5
2026
General meeting '26
27.5
2026
Interim report Q1'26
All
Research
Press releases
ShowingAll content types
Redeye: Saniona (Q3 Review) - Gearing up for clinical development
Saniona publishes its interim report for the third quarter of 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools